NYSE:AZN - AstraZeneca Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$37.05 +0.26 (+0.71 %)
(As of 05/23/2018 08:52 AM ET)
Previous Close$36.79
Today's Range$36.82 - $37.30
52-Week Range$28.43 - $37.30
Volume7.64 million shs
Average Volume4.32 million shs
Market Capitalization$93.19 billion
P/E Ratio8.66
Dividend Yield3.72%
Beta0.61

About AstraZeneca (NYSE:AZN)

AstraZeneca logoAstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:AZN
CUSIPN/A
Phone44-0-20-3749-5000

Debt

Debt-to-Equity Ratio1.08
Current Ratio0.73
Quick Ratio0.62

Price-To-Earnings

Trailing P/E Ratio8.66
Forward P/E Ratio21.79
P/E Growth1.94

Sales & Book Value

Annual Sales$22.47 billion
Price / Sales4.18
Cash Flow$3.3621 per share
Price / Cash11.02
Book Value$5.75 per share
Price / Book6.44

Profitability

EPS (Most Recent Fiscal Year)$4.28
Net Income$3.00 billion
Net Margins12.61%
Return on Equity30.73%
Return on Assets7.44%

Miscellaneous

Employees59,700
Outstanding Shares2,532,900,000

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semiannual dividend on Monday, February 5th. Shareholders of record on Friday, February 16th will be paid a dividend of $0.95 per share on Monday, March 19th. This represents a yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca's stock split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were payable to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca (NYSE:AZN) released its earnings results on Friday, May, 18th. The company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.20. The company earned $5.18 billion during the quarter, compared to analysts' expectations of $5.24 billion. AstraZeneca had a net margin of 12.61% and a return on equity of 30.73%. The business's quarterly revenue was down 4.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.99 EPS. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca issued an update on its FY18 earnings guidance on Friday, May, 18th. The company provided earnings per share (EPS) guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus estimate of $3.46.

What price target have analysts set for AZN?

18 brokers have issued 1-year target prices for AstraZeneca's shares. Their predictions range from $35.00 to $42.00. On average, they anticipate AstraZeneca's stock price to reach $38.1167 in the next twelve months. View Analyst Ratings for AstraZeneca.

Are investors shorting AstraZeneca?

AstraZeneca saw a decline in short interest during the month of April. As of April 30th, there was short interest totalling 8,995,025 shares, a decline of 24.0% from the April 13th total of 11,832,140 shares. Based on an average daily volume of 3,760,290 shares, the short-interest ratio is presently 2.4 days.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, Exec. Director & CEO (Age 59)
  • Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

Has AstraZeneca been receiving favorable news coverage?

News headlines about AZN stock have trended somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AstraZeneca earned a news sentiment score of 0.15 on Accern's scale. They also gave media stories about the company an impact score of 47.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.50%), Epoch Investment Partners Inc. (0.34%), BlackRock Inc. (0.26%), Schafer Cullen Capital Management Inc. (0.18%), Federated Investors Inc. PA (0.17%) and Wells Fargo & Company MN (0.15%). View Institutional Ownership Trends for AstraZeneca.

Which institutional investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Sei Investments Co., Wells Fargo & Company MN, Envestnet Asset Management Inc., Epoch Investment Partners Inc., Russell Investments Group Ltd., Farallon Capital Management LLC and Guggenheim Capital LLC. View Insider Buying and Selling for AstraZeneca.

Which institutional investors are buying AstraZeneca stock?

AZN stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Crawford Investment Counsel Inc., Senzar Asset Management LLC, Millennium Management LLC, Fisher Asset Management LLC, Global Financial Private Capital LLC, Thornburg Investment Management Inc. and PointState Capital LP. View Insider Buying and Selling for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $37.05.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $93.19 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 59,700 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, Cambridge X0, CB2 0AA. The company can be reached via phone at 44-0-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (AZN)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  519 (Vote Outperform)
Underperform Votes:  891 (Vote Underperform)
Total Votes:  1,410
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AstraZeneca (NYSE:AZN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
18 Wall Street analysts have issued ratings and price targets for AstraZeneca in the last 12 months. Their average twelve-month price target is $38.1167, suggesting that the stock has a possible upside of 2.88%. The high price target for AZN is $42.00 and the low price target for AZN is $35.00. There are currently 1 sell rating, 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.612.612.532.50
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.1167$38.1167$36.2583$34.7583
Price Target Upside: 2.88% upside10.00% upside7.98% upside4.54% upside

AstraZeneca (NYSE:AZN) Consensus Price Target History

Price Target History for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018BMO Capital MarketsSet Price TargetBuy$40.00LowView Rating Details
3/19/2018Jefferies GroupUpgradeHold ➝ Buy$28.43 ➝ $36.70LowView Rating Details
2/6/2018Leerink SwannBoost Price TargetMarket Perform ➝ Market Perform$36.00 ➝ $38.00MediumView Rating Details
2/5/2018Sanford C. BernsteinBoost Price TargetOutperform$40.00 ➝ $42.00HighView Rating Details
12/29/2017JPMorgan ChaseUpgradeNeutral ➝ OverweightLowView Rating Details
10/18/2017CitigroupUpgradeBuyN/AView Rating Details
10/17/2017CowenReiterated RatingHold$37.00N/AView Rating Details
10/16/2017Credit Suisse GroupUpgradeNeutral ➝ OutperformN/AView Rating Details
9/25/2017BNP ParibasUpgradeNeutral ➝ OutperformMediumView Rating Details
9/14/2017Liberum CapitalDowngradeBuy ➝ HoldLowView Rating Details
9/6/2017NatixisUpgradeNeutral ➝ BuyLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$35.00LowView Rating Details
8/9/2017InvestecUpgradeHold ➝ BuyLowView Rating Details
8/9/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
8/1/2017Pareto SecuritiesUpgradeSell ➝ HoldLowView Rating Details
7/28/2017Morgan StanleyDowngradeOverweight ➝ Equal WeightHighView Rating Details
7/13/2017Goldman SachsReiterated RatingSellHighView Rating Details
7/13/2017BarclaysReiterated RatingOverweightHighView Rating Details
4/5/2017UBSDowngradeBuy ➝ Neutral$35.44 ➝ $25.55N/AView Rating Details
2/21/2017Berenberg BankReiterated RatingBuyN/AView Rating Details
11/11/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
11/11/2016Beaufort SecuritiesReiterated RatingHoldN/AView Rating Details
11/10/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
11/10/2016Bank of AmericaReiterated RatingBuy$41.37N/AView Rating Details
11/10/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

AstraZeneca (NYSE:AZN) Earnings History and Estimates Chart

Earnings by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Earnings Estimates

2018 EPS Consensus Estimate: $1.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.42$0.42$0.42
Q2 20181$0.40$0.40$0.40
Q3 20181$0.39$0.39$0.39
Q4 20181$0.46$0.46$0.46

AstraZeneca (NYSE AZN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2018        
5/18/20183/31/2018$0.28$0.48$5.2360 billion$5.1780 billionViewListenView Earnings Details
2/2/2018Q4 2017$0.44$1.30$5.4936 billion$5.7770 billionViewListenView Earnings Details
11/9/2017Q3$0.57$1.12$5.9999 billion$6.2320 billionViewN/AView Earnings Details
7/27/20176/30/2017$0.41$0.87$5.0391 billion$5.0510 billionViewN/AView Earnings Details
4/27/20173/31/2017$0.38$0.99$5.4045 billion$5.4050 billionViewN/AView Earnings Details
2/2/2017Q416$0.51$1.21$5.43 billion$5.5850 billionViewListenView Earnings Details
11/10/2016Q316$0.48$1.32$5.95 billion$5.6990 billionViewN/AView Earnings Details
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.5970$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$0.52$1.21$6.0159 billion$5.8360 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.8724 billion$6.0570 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.6830 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.4398 billion$6.5420 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.4540 billionViewN/AView Earnings Details
4/29/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.5431 billion$6.3850 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.2820 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
4/27/2011Q1 2011$1.02$1.04ViewN/AView Earnings Details
1/27/2011Q4 2010$0.67$0.68ViewN/AView Earnings Details
10/27/2010Q3 2010$0.76$0.54ViewN/AView Earnings Details
7/30/2010Q2 2010$0.80$0.73ViewN/AView Earnings Details
4/29/2010Q1 2010$0.86$1.02ViewN/AView Earnings Details
10/29/2009Q3 2009$0.68$0.73ViewN/AView Earnings Details
7/30/2009Q2 2009$0.68$0.82ViewN/AView Earnings Details
1/29/2009Q4 2008$0.59$0.63ViewN/AView Earnings Details
4/24/2008Q1 2008$0.60$0.52ViewN/AView Earnings Details
1/31/2008Q4 2007$0.50$0.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AstraZeneca (NYSE:AZN) Dividend Information

AstraZeneca pays an annual dividend of $1.37 per share, with a dividend yield of 3.70%. AZN's most recent semiannual dividend payment was Monday, March 19. AstraZeneca pays out 32.01% of its earnings out as a dividend.
Most Recent Dividend:3/19/2018
Annual Dividend:$1.37
Dividend Yield:3.70%
Dividend Growth:-21.20% (3 Year Average)
Payout Ratio(s):32.01% (Trailing 12 Months of Earnings)
80.59% (Based on This Year's Estimates)
71.73% (Based on Next Year's Estimates)
40.75% (Based on Cash Flow)
Dividend Payments by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2018semiannual$0.955.62%2/15/20182/16/20183/19/2018
7/28/2017None$0.442.98%8/9/20178/11/20179/11/2017
2/3/2017semiannual$0.956.81%2/15/20172/17/20173/20/2017
7/29/2016$0.448/10/20168/12/20169/12/2016
2/5/2016$0.932/17/20162/19/20163/21/2016
2/10/2015semiannual$1.905.57%2/18/20152/20/20153/23/2015
8/1/2014semiannual$0.902.48%8/13/20148/15/20149/15/2014
2/10/2014special$1.902.79%2/19/20142/21/20143/24/2014
8/2/2013semiannual$0.903.52%8/14/20138/16/20139/16/2013
2/1/2013special$1.903.72%2/13/20132/15/20133/18/2013
(Data available from 1/1/2013 forward)

Insider Trades

AstraZeneca (NYSE AZN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 15.59%
Insider Trading History for AstraZeneca (NYSE:AZN)
Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE AZN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

AstraZeneca (NYSE AZN) News Headlines

Source:
DateHeadline
AstraZeneca Reports Regulatory Submission In Japan For Forxiga - Quick FactsAstraZeneca Reports Regulatory Submission In Japan For Forxiga - Quick Facts
www.nasdaq.com - May 21 at 8:12 AM
Form 6-K ASTRAZENECA PLC For: May 21Form 6-K ASTRAZENECA PLC For: May 21
www.streetinsider.com - May 21 at 8:12 AM
AstraZeneca potassium drug finally approved, threatening ViforAstraZeneca potassium drug finally approved, threatening Vifor
finance.yahoo.com - May 21 at 8:12 AM
FDAs OKs AstraZenecas Lokelma for hyperkalemiaFDA's OKs AstraZeneca's Lokelma for hyperkalemia
seekingalpha.com - May 21 at 7:11 AM
AstraZeneca Stock Dips On Weak Q1 Profit; Backs FY18 ViewAstraZeneca Stock Dips On Weak Q1 Profit; Backs FY18 View
www.nasdaq.com - May 19 at 8:08 AM
AstraZeneca Shareholder Approves All ResolutionsAstraZeneca Shareholder Approves All Resolutions
www.nasdaq.com - May 19 at 8:08 AM
AstraZenecas (AZN) Q1 Earnings & Sales Miss, Stock DownAstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
www.msn.com - May 19 at 8:08 AM
AstraZeneca insists future is bright after big Crestor sales hitAstraZeneca insists future is bright after big Crestor sales hit
finance.yahoo.com - May 19 at 8:08 AM
AstraZenecas (AZN) CEO Pascal Soriot on Q1 2018 Results - Earnings Call TranscriptAstraZeneca's (AZN) CEO Pascal Soriot on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 19 at 8:08 AM
LOKELMATM Approved in the US for the Treatment of Adults with HyperkalemiaLOKELMATM Approved in the US for the Treatment of Adults with Hyperkalemia
finance.yahoo.com - May 18 at 6:05 PM
AstraZeneca plc Stock Slips on Q1 Earnings Miss, Falling Crestor SalesAstraZeneca plc Stock Slips on Q1 Earnings Miss, Falling Crestor Sales
investorplace.com - May 18 at 12:24 PM
AstraZeneca (AZN) Issues Quarterly  Earnings ResultsAstraZeneca (AZN) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 18 at 9:32 AM
AstraZeneca (AZN) Releases FY18 Earnings GuidanceAstraZeneca (AZN) Releases FY18 Earnings Guidance
www.americanbankingnews.com - May 18 at 8:58 AM
BRIEF-AstraZeneca CEO Says More Drug Industry Consolidation PossibleBRIEF-AstraZeneca CEO Says More Drug Industry Consolidation Possible
www.reuters.com - May 18 at 8:29 AM
BRIEF-Astrazeneca CEO Says In Ongoing Discussions With Investors On BonusesBRIEF-Astrazeneca CEO Says In Ongoing Discussions With Investors On Bonuses
www.reuters.com - May 18 at 8:29 AM
AstraZeneca quarterly profit drops, sales riseAstraZeneca quarterly profit drops, sales rise
www.marketwatch.com - May 18 at 8:29 AM
AstraZeneca Q1 revenues down 4%; shares off 2% premarketAstraZeneca Q1 revenues down 4%; shares off 2% premarket
seekingalpha.com - May 18 at 6:52 AM
AstraZeneca hit by falling Crestor sales, higher costsAstraZeneca hit by falling Crestor sales, higher costs
www.cnbc.com - May 18 at 3:48 AM
AstraZeneca (AZN) Said to Weigh Sale of US Rights to Crestor, Could Fetch Over $1 Billion - BloombergAstraZeneca (AZN) Said to Weigh Sale of US Rights to Crestor, Could Fetch Over $1 Billion - Bloomberg
www.streetinsider.com - May 16 at 8:15 AM
Emulate, Inc. and AstraZeneca Form Strategic Agreement to Work Side-by-Side on Organs-on-Chips Technology to ...Emulate, Inc. and AstraZeneca Form Strategic Agreement to Work Side-by-Side on Organs-on-Chips Technology to ...
www.businesswire.com - May 16 at 8:15 AM
Short Interest in AstraZeneca (AZN) Decreases By 24.0%Short Interest in AstraZeneca (AZN) Decreases By 24.0%
www.americanbankingnews.com - May 16 at 1:08 AM
AstraZeneca (AZN) PT Raised to $41 at BMO CapitalAstraZeneca (AZN) PT Raised to $41 at BMO Capital
www.streetinsider.com - May 15 at 8:21 AM
Free Stock Performance Review on Pfizer and Three More Drug Makers’ StocksFree Stock Performance Review on Pfizer and Three More Drug Makers’ Stocks
finance.yahoo.com - May 15 at 8:21 AM
DPS Group gana un contrato en Suecia de AstraZenecaDPS Group gana un contrato en Suecia de AstraZeneca
www.prnewswire.com - May 15 at 2:46 AM
AstraZeneca Schweden vergibt Auftrag an DPS GroupAstraZeneca Schweden vergibt Auftrag an DPS Group
www.prnewswire.com - May 15 at 2:46 AM
DPS Group vinner kontrakt med AstraZeneca i SverigeDPS Group vinner kontrakt med AstraZeneca i Sverige
www.prnewswire.com - May 15 at 2:46 AM
DPS Group remporte un contrat en Suède auprès dAstraZenecaDPS Group remporte un contrat en Suède auprès d'AstraZeneca
www.prnewswire.com - May 15 at 2:46 AM
DPS Group Wins Contract in Sweden from AstraZenecaDPS Group Wins Contract in Sweden from AstraZeneca
www.prnewswire.com - May 15 at 2:46 AM
AstraZeneca Sees A Phase 3 Flop, But Not All Is LostAstraZeneca Sees A Phase 3 Flop, But Not All Is Lost
seekingalpha.com - May 14 at 8:21 AM
Big Pharma Diversification Strategies Report 2018: Roche, Johnson & Johnson, and AstraZeneca - Active Acquirers in ...Big Pharma Diversification Strategies Report 2018: Roche, Johnson & Johnson, and AstraZeneca - Active Acquirers in ...
www.businesswire.com - May 11 at 8:19 AM
AstraZeneca COPD drug fails phase 3 trialAstraZeneca COPD drug fails phase 3 trial
www.marketwatch.com - May 11 at 8:19 AM
AstraZenecas Fasenra Fails in Trial of Severe Lung DiseaseAstraZeneca's Fasenra Fails in Trial of Severe Lung Disease
finance.yahoo.com - May 11 at 8:19 AM
AstraZeneca (AZN) to Release Earnings on FridayAstraZeneca (AZN) to Release Earnings on Friday
www.americanbankingnews.com - May 11 at 1:02 AM
What Analysts Recommend for Merck and Peers in MayWhat Analysts Recommend for Merck and Peers in May
finance.yahoo.com - May 10 at 6:02 PM
How Merck’s Human Vaccines Business Performed in 1Q18How Merck’s Human Vaccines Business Performed in 1Q18
finance.yahoo.com - May 9 at 8:15 AM
AstraZeneca (AZN), Merck (MRK) LYNPARZA Tablets Receive EU Approval for Treatment of Platinum-Sensitive ...AstraZeneca (AZN), Merck (MRK) LYNPARZA Tablets Receive EU Approval for Treatment of Platinum-Sensitive ...
www.streetinsider.com - May 8 at 8:13 AM
AstraZeneca sells rights for Seroquel to Luye Pharma for $538 millionAstraZeneca sells rights for Seroquel to Luye Pharma for $538 million
finance.yahoo.com - May 8 at 8:13 AM
Procella Therapeutics and Smartwise Enter Collaboration With AstraZeneca to Develop Novel Cardiovascular and Catheter-based TherapiesProcella Therapeutics and Smartwise Enter Collaboration With AstraZeneca to Develop Novel Cardiovascular and Catheter-based Therapies
www.prnewswire.com - May 7 at 5:13 AM
AstraZeneca (AZN) Downgraded by ValuEngineAstraZeneca (AZN) Downgraded by ValuEngine
www.americanbankingnews.com - May 4 at 12:20 AM
GlaxoSmithKline’s Pharmaceutical Business in 1Q18GlaxoSmithKline’s Pharmaceutical Business in 1Q18
finance.yahoo.com - April 30 at 8:18 AM
AstraZeneca (AZN) Given Average Rating of "Buy" by BrokeragesAstraZeneca (AZN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 29 at 5:57 PM
AstraZeneca Says Tagrisso Receives Positive EU CHMP OpinionAstraZeneca Says Tagrisso Receives Positive EU CHMP Opinion
www.nasdaq.com - April 27 at 8:26 AM
Biotech Analysis Central Pharma News: AstraZenecas Fumble, Acadias Nuplazid Review, Catabasis Second Success ...Biotech Analysis Central Pharma News: AstraZeneca's Fumble, Acadia's Nuplazid Review, Catabasis' Second Success ...
seekingalpha.com - April 27 at 8:26 AM
Novo Nordisk’s Victoza Could See High Growth in 2018Novo Nordisk’s Victoza Could See High Growth in 2018
finance.yahoo.com - April 26 at 8:13 AM
BRIEF-AstraZeneca disappointed by data from Arctic trial in third-line non-small cell lung cancerBRIEF-AstraZeneca disappointed by data from Arctic trial in third-line non-small cell lung cancer
www.reuters.com - April 24 at 8:16 AM
BRIEF-Redx Pharma Appoints Astrazeneca Executive Lisa Anson As CEOBRIEF-Redx Pharma Appoints Astrazeneca Executive Lisa Anson As CEO
www.reuters.com - April 24 at 8:16 AM
AstraZeneca: Cancer-drug combo stumbles in trialAstraZeneca: Cancer-drug combo stumbles in trial
www.marketwatch.com - April 24 at 8:16 AM
AstraZeneca flop a fresh blow to cancer immunotherapy combinationAstraZeneca flop a fresh blow to cancer immunotherapy combination
finance.yahoo.com - April 24 at 8:16 AM
AstraZeneca to raise stake in Circassia to up to 19.9 percentAstraZeneca to raise stake in Circassia to up to 19.9 percent
finance.yahoo.com - April 24 at 8:16 AM
3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close
seekingalpha.com - April 21 at 8:16 AM

SEC Filings

AstraZeneca (NYSE:AZN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AstraZeneca (NYSE:AZN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AstraZeneca (NYSE AZN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.